The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Previously, for similar presentations, we’ve been told that no new material information will be released. As this same statement isn’t in the recent RNS there is a high probability material information will be released before the presentation on Wednesday.
If this is the current offering then it should not take long to become the new standard.
https://amp.cancer.org/treatment/treatments-and-side-effects/treatment-types/tumor-agnostic-drugs.html
Paras from here.
https://www.cancer.net/blog/2018-12/tumor-agnostic-treatment-cancer-expert-perspective
Came across this a few hours ago that discusses agnostic. Two paras are very interesting. Suggesting to me that things could soon progress very quickly.
Doctors and scientists are always looking for better ways to care for people with cancer. To make scientific advances, doctors create research studies involving volunteers, called clinical trials. Every FDA-approved drug was tested in clinical trials. In most clinical trials, the volunteers are people with the same type of cancer. However, tumor-agnostic treatments are often studied in a special type of clinical trial called a “basket trial.
Many of these genetic changes are rare, and basket trials offer a more efficient way to study a drug in tumors with rare genetic changes. In traditional clinical trials, which usually test the effects of a drug in a single type of cancer, it is often very hard to find enough people with cancer with a rare genetic mutation who can volunteer for a study. Basket trials can be particularly useful in the study of rare cancers or cancer with rare mutations.
To DE 5 & beyond.
“The Safety Data Monitoring Committee (SDMC) has recommended continuation to higher dose cohorts with the aim of identifying a maximum tolerated dose (MTD) necessary to inform the dosing levels for the phase 1b and future studies. The Company expects that it will complete these additional cohorts during the first half of 2023.”
Already started. Though the Jan RNS could have been more explicit. It said, Safety Data Monitoring Committee (SDMC) has recommended continuation to higher dose cohorts with the aim of identifying a maximum tolerated dose (MTD) necessary to inform the dosing levels for the phase 1b and future studies. The Company expects that it will complete these additional cohorts during the first half of 2023.’
Note it says ‘complete’ and not start and complete. So already underway.
C5 has started. But the vagueness has caused fear, uncertainty and doubt. Should have mentioned ‘already started’ and not just ‘complete’.
Note that there is more than C5. ‘Cohorts’ is plural.
17/01/23 RNS - The Company expects that it will complete these additional cohorts during the first half of 2023.
Live, I’m unsure that flipping between P2RD & MTD has any bearing on the timing of Phase 1b. This was being discussed with regards this aspect of the current aims possibly affecting the SP. Personally, I can understand P2RD if there is no MTD. But the emphasis in my mind has shifted back to MTD. So feel unsure. Others may feel the same.
Timster et al, you have to look further back than last December to verify the emphasis was on getting a Phase 2 Recommended Dose (P2RD) rather than Maximum Tolerable Dose (MTD). This was because a MTD may not be found. After all, AVA6K is safer than what it will replace.